Special Seminar

Liver Fibrosis – Pathogenesis and Links to Hepatocellular Carcinoma

Scott L. Friedman, M.D.

Dean for Therapeutic Discovery, Professor of Medicine, Professor of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, NY

Chief, Division of Liver Diseases, The Mount Sinai Hospital, New York, NY

Friday, January 25, 2013 13:00-14:00

CHUV, Auditoire Yersin

Dr. Scott L. Friedman has performed pioneering research into the mechanisms of fibrosis in chronic liver disease, was the first to isolate and characterize the hepatic stellate cell, which is the key cell type responsible for scar production in liver, and is actively involved in the development of novel antifibrotic strategies. His laboratory has also discovered a novel tumor suppressor gene, KLF6, that is inactivated in a number of human cancers including hepatocellular carcinoma (HCC).

Dr. Friedman graduated from Mount Sinai School of Medicine, was a Medical Resident at the Beth Israel Hospital, Harvard Medical School, Boston, then a Gastroenterology Fellow at UCSF before assuming a faculty position there, which he held for ten years. During a 1995-1996 sabbatical from UCSF he was a Fulbright Scholar and Visiting Professor at the Weizmann Institute of Science in Israel. In 1997 he moved to Mount Sinai as Director of Liver Research, then became Division Chief in 2001.

Dr. Friedman has given invited lectures throughout the world, and he is a respected clinician and teacher. Among many other distinctions, he was awarded the Hans Popper International Liver Research Prize in 2003, he was the President of the American Association for the Study of the Liver (AASLD) in 2009, and he received the EASL International Recognition Award in 2012.

Given the increasing burden of chronic liver disease and HCC Dr. Friedman’s research is of utmost timeliness and importance, and I am certain that his seminar will be a memorable highlight.